Best practices for the development and fit-for-purpose validation of biomarker methods: a conference report
Tóm tắt
This conference report summarized a full-day workshop, “best practices for the development and fit-for-purpose validation of biomarker methods,” which was held prior to the American Association of Pharmaceutical Scientists (AAPS) PharmSci360 Congress, San Antonio, TX, November 2019. The purpose of the workshop was to bring together thought leaders in biomarker assay development in order to identify which assay parameters and key statistical measures need to be considered when developing a biomarker assay. A diverse group of more than 40 scientists participated in the workshop. The workshop and subsequent working dinner stimulated robust discussion. While a consensus on best practices was not achieved, some common themes and major points to consider for biomarker assay development have been identified and agreed on. The focus of this conference report is to summarize the presentations and discussions which occurred at the workshop. Biomarker assay validation is a complex and an evolving area with discussions ongoing.
Tài liệu tham khảo
CLSI (ed) (2021) Validation of Assays Performed by Flow Cytometry. Clinical and Laboratory Standards Institute 1st ed. CLSI document H62. Clinical Laboratory Standards Institute, Wayne
Cossarizza A, Chang HD, Radbruch A et al (2019) Guidelines for the use of flow cytometry and cell sorting in immunological studies (second edition). Eur J Immunol 49(10):1457–1973
Cowan KJ, Amaravadi L, Cameron MJ et al (2017) Recommendations for selection and characterization of protein biomarker assay calibrator material. AAPS J 19(6):1550–1563
Dakappagari N, Zhang H, Stephen L, Amaravadi L, Khan MU (2017) Recommendations for clinical biomarker specimen preservation and stability assessments. Bioanalysis 9(8):643–653
Goodman J, Cowan KJ, Golob M, Karlsson L, Kunz U, Nelson R, Ulrichts H, Stevenson L, Terry L, Timmerman P (2020 Oct) Update to the European Bioanalysis Forum recommendation on biomarkers assays; bringing context of use into practice. Bioanalysis. 12(20):1427–1437
Hu WT, Watts KD, Shaw LM et al (2015) CSF beta-amyloid 1-42 - what are we measuring in Alzheimer’s disease? Ann Clin Transl Neurol 2(2):131–139
Islam R, Briscoe C, Bower J et al (2018) 11th GCC Closed Forum: cumulative stability; matrix stability; immunogenicity assays; laboratory manuals; biosimilars; chiral methods; hybrid LBA/LCMS assays; fit-for-purpose validation; China Food and Drug Administration bioanalytical method validation. Bioanalysis 10(7):433–444
Jani D, Allinson J, Berisha F et al (2016) Recommendations for use and fit-for-purpose validation of biomarker multiplex ligand binding assays in drug development. AAPS J 18(1):1–14
Kalina T, Lundsten K, Engel P (2020) Relevance of antibody validation for flow cytometry. Cytometry A 97(2):126–136
Lee JW, Devanarayan V, Barrett YC et al (2006) Fit-for-purpose method development and validation for successful biomarker measurement. Pharm Res 23(2):312–328
Lee JW, Weiner RS, Sailstad JM et al (2005) Method validation and measurement of biomarkers in nonclinical and clinical samples in drug development: a conference report. Pharm Res 22(4):499–511
Mathews JA, Ni YG, Wang C et al (2020) Considerations for soluble protein biomarker blood sample matrix selection. AAPS J 22(2):38
Menetski JP, Hoffmann SC, Cush SS et al (2019) The Foundation for the National Institutes of Health Biomarkers Consortium: past accomplishments and new strategic direction. Clin Pharmacol Ther 105(4):829–843
Piccoli P, Sauer JM (2019) Points to Consider Document: Scientific and Regulatory Considerations for the Analytical Validation of Assays Used in the Qualification of Biomarkers in Biological Matrices. https://c-path.org/wp-content/uploads/2019/06/evidconsid-whitepaper-analyticalsectionv2019.pdf.
Piccoli S, Mehta D, Vitaliti A et al (2019) 2019 white paper on recent issues in bioanalysis: FDA immunogenicity guidance, gene therapy, critical reagents, biomarkers and flow cytometry validation (part 3 - recommendations on 2019 FDA immunogenicity guidance, gene therapy bioanalytical challenges, strategies for critical reagent management, biomarker assay validation, flow cytometry validation & CLSI H62). Bioanalysis 11(24):2207–2244
Piccoli SP, Garofolo F (2018) Biomarker assay validation. Bioanalysis 10(12):889–891
Sant GR, Knopf KB, Albala DM (2017) Live-single-cell phenotypic cancer biomarkers-future role in precision oncology? NPJ Precis Oncol 1(1):21
Stevenson LF (2019) Evolving our thinking on biomarker assay validation: are we ready for the next leap? Bioanalysis 11(7):571–573
US Department of Health and Human Services, Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Bioanalytical method validation. Guidance for industry. (2018). https://www.fda.gov/files/drugs/published/Bioanalytical-Method-Validation-Guidance-for-Industry.pdf.
US Department of Health and Human Services Food and Drug Administration. Center for Drug Evaluation and Research (CDER). Bioanalytical methods templates - technical specifications document. https://www.fda.gov/media/131425/download 2019.
Wang YC, Strauss DG, Huang SM (2019) Use of pharmacodynamic/response biomarkers for therapeutic biologics regulatory submissions. Biomark Med 13(10):805–809